AlphAIAlphAI — Financial news for AI agents
tradingview.comOCT 11 min read$ANGO

ANGO Q1'26 Earnings: revenue estimate is 80.51M USD

AngioDynamics (ANGO) will report Q1'26 earnings on October 8. Analysts expect revenue of 80.51M USD and EPS of (0.11) USD.

Original reporting
tradingview.com
Published Oct 1, 2026, 11:00 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 1, 2026, 11:06 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
ANGO Q1'26 Earnings: revenue estimate is 80.51M USD — source image
Source · tradingview.com
Decision brief

The 30-second read

$ANGONeutralMed
01

Why it matters

The disclosed Q1'26 estimate provides the first concrete data point for the quarter, enabling traders to set positions before the actual release.

02

Market read

The earnings preview is the primary catalyst for ANGO today; no broader market move is expected.

03

What to watch

Potential hidden cost pressures or upcoming regulatory approvals could swing results beyond the simple revenue estimate.

Relevance 6/10Novelty 7/10Timing: pre‑market on Oct 8

Background

AngioDynamics is a small‑cap medical‑device company that reports quarterly earnings.

Company-level read

Ticker impact

$ANGONeutralHigh confidence
Context

AngioDynamics (ANGO) will release Q1'26 earnings on Oct 8 with revenue estimate of $80.51M and EPS of -$0.11.

Expected impact

potential downside if actual results miss the estimate, upside if they beat it

Evidence & confidence

Guidance is the first disclosed figure for this quarter; traders can position ahead of the release.

Market effects

Sector

AngioDynamics operates in the medical device sector; its guidance may influence peer sentiment.

Regional

Impact limited to US small‑cap and biotech investors.

Global

Minimal global effect beyond niche medical‑device investors.

Counterpoint

What could challenge this read

If the market overreacts to a modest estimate, a short position could profit on a post‑release rally.

Key entities

  • Company
    AngioDynamics, Inc.

    US‑listed medical‑device firm (ticker ANGO).

Read at source← All news

Related articles

OCT 14
$ANGOMed

AngioDynamics Announces Humana Medicare Advantage Coverage Policy Supporting Broader Access to NanoKnife IRE for Prostate and Liver Cancer

AngioDynamics announced that Humana updated its Medicare Advantage coverage policy to include NanoKnife IRE for prostate and liver cancer, effective October 1, 2026. This follows recent reimbursement milestones, including new CPT codes and Palmetto GBA's LCD L40205. Humana, with 7 million members, will use LCD L40205 criteria for coverage, subject to prior authorization.

marketscreener.com2 min
OCT 14
$ANGOMed

H.C. Wainwright cuts AngioDynamics stock price target to $18

H.C. Wainwright reduced its price target for AngioDynamics (ANGO) to $18 from $19, maintaining a Buy rating. The company reported fiscal Q1 2027 net sales of $80.9M, up 6.9% YoY, but a net loss of $7.1M. Guidance for fiscal 2027 includes revenue of $336M-$341M and adjusted EBITDA of $13M-$16M. Canaccord Genuity reiterated its Buy rating with a $20 target, citing growth in key platforms. The stock fell 23% post-earnings.

investing.com2 min
OCT 14
$ANGOMed

AngioDynamics Announces Humana Medicare Advantage Coverage Polic

AngioDynamics (ANGO) announced Humana's updated Medicare Advantage coverage policy for its NanoKnife System, effective October 1, 2026. The policy applies LCD L40205 criteria for IRE technology, covering eligible patients with intermediate-risk prostate cancer and certain liver tumors. This follows recent reimbursement milestones, including CPT codes and Palmetto GBA's LCD. Humana, with 7 million members, will use LCD L40205 criteria for consistent coverage.

gurufocus.com2 min
OCT 9
$ANGOHigh

AngioDynamics (ANGO) Q1 2027 Earnings Call Transcript

AngioDynamics (ANGO) reported Q1 2027 revenue growth of 7%, with the MedTech segment up 13%. Auryon saw 14.7% growth, marking 21 consecutive quarters of double-digit gains. AlphaVac revenue rose 37.4% year-over-year. The company named Eric Honer as its new CEO, effective November 2. NanoKnife received FDA approval for a BPH study, targeting a $1.9B market. Med Device segment grew 1.4%.

finance.yahoo.com5 min
OCT 8
$ANGOHighAI 8/10

AngioDynamics, Inc. Q1 2027 Earnings Call Summary

AngioDynamics reported Q1 2027 earnings, with MedTech segment revenue growing 13.2% YoY, now 49% of total revenue. Auryon saw 21st straight quarter of double-digit growth. NanoKnife adoption increased, with record procedure volumes. Full-year revenue guidance is $336M-$341M, with MedTech expected to dominate. Gross margin expanded 410 bps due to pricing and mix shift. Eric Honer appointed as new CEO. The company remains debt-free and expects positive cash flow for the year.

finance.yahoo.com3 min